Matches in SemOpenAlex for { <https://semopenalex.org/work/W3125280317> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- W3125280317 abstract "During glioblastoma treatment, the pharmaceutical monoclonal antibody to VEGF, bevacizumab, has improved quality of life and delayed progression for several months but has not, or only marginally prolonged overall survival. In 2017 several dramatic research papers appeared that are crucial to our understanding of glioblastoma vis a vis the mode of action of bevacizumab. As a consequence of these papers, a new, potentially more effective, treatment protocol can be built around bevacizumab. This is the ADZT Regimen where four old drugs are added to bevacizumab. These four are apremilast, marketed to treat psoriasis, dapsone, marketed to treat Hansen’s disease, zonisamide, marketed to treat seizures, and telmisartan, marketed to treat hypertension. The ancillary attributes of each of these drugs has been shown to augment bevacizumab. This paper will detail the research data supporting that contention." @default.
- W3125280317 created "2021-02-01" @default.
- W3125280317 creator A5016608605 @default.
- W3125280317 date "2018-09-12" @default.
- W3125280317 modified "2023-09-25" @default.
- W3125280317 title "Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment" @default.
- W3125280317 doi "https://doi.org/10.20944/preprints201809.0209.v1" @default.
- W3125280317 hasPublicationYear "2018" @default.
- W3125280317 type Work @default.
- W3125280317 sameAs 3125280317 @default.
- W3125280317 citedByCount "0" @default.
- W3125280317 crossrefType "posted-content" @default.
- W3125280317 hasAuthorship W3125280317A5016608605 @default.
- W3125280317 hasBestOaLocation W31252803171 @default.
- W3125280317 hasConcept C126322002 @default.
- W3125280317 hasConcept C143998085 @default.
- W3125280317 hasConcept C2776364478 @default.
- W3125280317 hasConcept C2776694085 @default.
- W3125280317 hasConcept C2777802072 @default.
- W3125280317 hasConcept C2779609412 @default.
- W3125280317 hasConcept C2781413609 @default.
- W3125280317 hasConcept C71924100 @default.
- W3125280317 hasConcept C98274493 @default.
- W3125280317 hasConceptScore W3125280317C126322002 @default.
- W3125280317 hasConceptScore W3125280317C143998085 @default.
- W3125280317 hasConceptScore W3125280317C2776364478 @default.
- W3125280317 hasConceptScore W3125280317C2776694085 @default.
- W3125280317 hasConceptScore W3125280317C2777802072 @default.
- W3125280317 hasConceptScore W3125280317C2779609412 @default.
- W3125280317 hasConceptScore W3125280317C2781413609 @default.
- W3125280317 hasConceptScore W3125280317C71924100 @default.
- W3125280317 hasConceptScore W3125280317C98274493 @default.
- W3125280317 hasLocation W31252803171 @default.
- W3125280317 hasLocation W31252803172 @default.
- W3125280317 hasLocation W31252803173 @default.
- W3125280317 hasOpenAccess W3125280317 @default.
- W3125280317 hasPrimaryLocation W31252803171 @default.
- W3125280317 hasRelatedWork W2007136227 @default.
- W3125280317 hasRelatedWork W2101986864 @default.
- W3125280317 hasRelatedWork W2129608087 @default.
- W3125280317 hasRelatedWork W2405544616 @default.
- W3125280317 hasRelatedWork W2965226729 @default.
- W3125280317 hasRelatedWork W3088178260 @default.
- W3125280317 hasRelatedWork W4210760604 @default.
- W3125280317 hasRelatedWork W4238628545 @default.
- W3125280317 hasRelatedWork W4281640295 @default.
- W3125280317 hasRelatedWork W93522246 @default.
- W3125280317 isParatext "false" @default.
- W3125280317 isRetracted "false" @default.
- W3125280317 magId "3125280317" @default.
- W3125280317 workType "article" @default.